Seattle Genetics: Q4 & FY 2015 Results (Seattle Genetics, Inc) - Feb 10, 2016 - Anticipated data from P1/2 trial (NCT02614560) as a pre-conditioning regimen prior to an allogeneic stem cell transplant and also for use as maintenance therapy following transplant in AML patients in 2016
Anticipated P1/2 data • Acute Myelogenous Leukemia • Hematological Malignancies
|